Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector
Sort by: Date|Relevance

Bringing Hope to People Living with Neurodegenerative Diseases

Alpha Cognition Inc. ( TSX-V.ACOG , OTCMKTS: ACOGF , Forum ) is a clinical stage, biopharmaceutical company dedicated to developing treatments for under-served neurodegenerative diseases. Stockhouse Media’s Dave Jackson caught up recently with Company CE...
Dave Jackson | October 20, 2021 |

Hemostemix Founder: A Man with a Compassionate Heart

The Canadian stem cell company Hemostemix Inc. ( TSX-V: HEM , OTC: HMTXF ) was founded by a man who truly had a compassionate heart and a clear intent to establish a breakthrough in heart disease using the same technology that saved his life. Roger Bergersen, who train...
Featured Submission | December 14, 2020 |

Axsome Therapeutics Investors Awaken to Positive Outcome in Phase 2 Narcolepsy Trial

Axsome Therapeutics shares traded 14% higher today after the company reported that its narcolepsy drug candidate AXS-12 achieved its primary endpoint in the Phase 2 CONCERT Study. This morning before U.S. markets opened, clinical-stage biopharmaceutical company Axsom...
Streetwise Reports | December 4, 2019 |

East-West Trade War: Never Take a Knife to a Gunfight

It's a funny thing that happens when the stress of financial insolvency bubbles up to the surface. Decisions once considered "routine" (like brushing one's teeth or walking one's dog) suddenly have life-or-death outcomes, complete with cold sweats, sleepless nights and ...
Streetwise Reports | October 11, 2019 |

Invasive Species

Invasive species: Any kind of living organism—an amphibian (like the cane toad), plant, insect, fish, fungus, bacteria, or even an organism's seeds or eggs—that is not native to an ecosystem and causes harm. They can harm the environment, the economy, or even human he...
Streetwise Reports | August 14, 2019 |

A Boomer's Plea

I was born in the 1950s, a decade dominated by thousands of WWII servicemen marrying and starting families in the creation of the largest demographic in history, the "Baby Boom Generation." The 1950s saw Elvis Presley dominate the entertainment industry with ten #1 hits a...
Streetwise Reports | April 22, 2020 |

ACADIA Pharma's Shares Open 75% Higher on Positive Anti-Psychosis Drug Phase 3 Results

Shares of ACADIA Pharmaceuticals opened up 75% higher today after the company announced that its Phase 3 Study of pimavanserin for the treatment of dementia-related psychosis met its primary endpoint. San Diego, Calif.-based biopharmaceutical company ACADIA Pharmaceu...
Streetwise Reports | September 10, 2019 |

Ra Pharmaceuticals Shares Up 100% Following $2.1 Billion Takeover Bid

Shares of Ra Pharmaceuticals doubled today after the firm announced that it will be acquired by Belgian firm UCB for $48 per share in an all cash deal. Prior to the market open this morning Ra Pharmaceuticals Inc. (RARX:NASDAQ) and Brussels-based UCB (UCB:Euronext)...
Streetwise Reports | October 11, 2019 |

Sarepta Shares Get a 35% Boost from FDA Approval of 2nd DMD Drug

Sarepta Therapeutics shares traded 35% higher after the firm reported that the FDA approved its second RNA exon-skipping treatment drug VYONDYS 53 injection for the treatment of Duchenne's Muscular Dystrophy in patients amenable to skipping Exon 53. Yesterday evening,...
Streetwise Reports | December 16, 2019 |

Biotech Announces Deal with Bayer on Non-Hormonal Contraception

Details of the arrangement and an update on the company's pipeline are provided in a Dawson James report. In a Jan. 13 research note, Dawson James Securities analyst Jason Kolbert reported that Daré Bioscience Inc. (DARE:NASDAQ) partnered with Bayer, the company beh...
Streetwise Reports | January 16, 2020 |
1 2 3 4 5 6 7 8 9 10 ...